CA1224782A - Thieno(2,3-d) pyrimidine derivatives and salts thereof - Google Patents
Thieno(2,3-d) pyrimidine derivatives and salts thereofInfo
- Publication number
- CA1224782A CA1224782A CA000471183A CA471183A CA1224782A CA 1224782 A CA1224782 A CA 1224782A CA 000471183 A CA000471183 A CA 000471183A CA 471183 A CA471183 A CA 471183A CA 1224782 A CA1224782 A CA 1224782A
- Authority
- CA
- Canada
- Prior art keywords
- thieno
- carbon atoms
- group
- general formula
- pyrimidine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- DDWBRNXDKNIQDY-UHFFFAOYSA-N thieno[2,3-d]pyrimidine Chemical class N1=CN=C2SC=CC2=C1 DDWBRNXDKNIQDY-UHFFFAOYSA-N 0.000 title claims abstract description 13
- 150000003839 salts Chemical class 0.000 title claims abstract description 8
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 22
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 15
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 12
- 239000001257 hydrogen Substances 0.000 claims abstract description 12
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical class [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 9
- 150000002367 halogens Chemical class 0.000 claims abstract description 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 5
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims abstract description 3
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 claims abstract description 3
- 125000002993 cycloalkylene group Chemical group 0.000 claims abstract description 3
- 150000001875 compounds Chemical class 0.000 claims description 37
- 238000000034 method Methods 0.000 claims description 19
- 230000008569 process Effects 0.000 claims description 12
- 125000001424 substituent group Chemical group 0.000 claims description 7
- 125000003277 amino group Chemical group 0.000 claims description 6
- 125000006239 protecting group Chemical group 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims 3
- 210000004556 brain Anatomy 0.000 abstract description 2
- 230000004064 dysfunction Effects 0.000 abstract description 2
- 125000005843 halogen group Chemical group 0.000 abstract description 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 42
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 24
- 238000006243 chemical reaction Methods 0.000 description 23
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 15
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical group C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 14
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 150000001412 amines Chemical class 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- -1 homopiperazinyl group Chemical group 0.000 description 7
- 238000002844 melting Methods 0.000 description 7
- 230000008018 melting Effects 0.000 description 7
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 7
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 230000003042 antagnostic effect Effects 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 150000003230 pyrimidines Chemical class 0.000 description 6
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 5
- 208000000044 Amnesia Diseases 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 5
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 5
- QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 5
- 229960003147 reserpine Drugs 0.000 description 5
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 239000000460 chlorine Substances 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 229910000029 sodium carbonate Inorganic materials 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 208000031091 Amnestic disease Diseases 0.000 description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000006986 amnesia Effects 0.000 description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 239000011737 fluorine Substances 0.000 description 3
- 230000002631 hypothermal effect Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 239000011630 iodine Substances 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- PMJWPOLCDWAZAZ-UHFFFAOYSA-N 2-chloro-6-methyl-4-phenylthieno[2,3-d]pyrimidine Chemical compound N1=C(Cl)N=C2SC(C)=CC2=C1C1=CC=CC=C1 PMJWPOLCDWAZAZ-UHFFFAOYSA-N 0.000 description 2
- JVBZWPQNEHZXOV-UHFFFAOYSA-N 6-methyl-4-phenyl-2-piperazin-1-ylthieno[2,3-d]pyrimidine Chemical compound N1=C2SC(C)=CC2=C(C=2C=CC=CC=2)N=C1N1CCNCC1 JVBZWPQNEHZXOV-UHFFFAOYSA-N 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- GMZVRMREEHBGGF-UHFFFAOYSA-N Piracetam Chemical compound NC(=O)CN1CCCC1=O GMZVRMREEHBGGF-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical group C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 2
- 229960000836 amitriptyline Drugs 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 231100000863 loss of memory Toxicity 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 229960004526 piracetam Drugs 0.000 description 2
- 230000000506 psychotropic effect Effects 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical group C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- AJHHBXWRFMFIGP-UHFFFAOYSA-N 1-(4-fluorophenyl)-2-[4-(6-methyl-4-phenylthieno[2,3-d]pyrimidin-2-yl)piperazin-1-yl]ethanol Chemical compound N1=C2SC(C)=CC2=C(C=2C=CC=CC=2)N=C1N(CC1)CCN1CC(O)C1=CC=C(F)C=C1 AJHHBXWRFMFIGP-UHFFFAOYSA-N 0.000 description 1
- YVLDOAPIQHZBQC-UHFFFAOYSA-N 1-(4-fluorophenyl)-2-[4-(6-methyl-4-phenylthieno[2,3-d]pyrimidin-2-yl)piperazin-1-yl]ethanone Chemical compound N1=C2SC(C)=CC2=C(C=2C=CC=CC=2)N=C1N(CC1)CCN1CC(=O)C1=CC=C(F)C=C1 YVLDOAPIQHZBQC-UHFFFAOYSA-N 0.000 description 1
- QOFUDSPYJDXBOF-UHFFFAOYSA-N 1-benzyl-3-methylpiperazine Chemical compound C1CNC(C)CN1CC1=CC=CC=C1 QOFUDSPYJDXBOF-UHFFFAOYSA-N 0.000 description 1
- UURUUHYFPCRBID-UHFFFAOYSA-N 2-(6-methyl-2-piperazin-1-ylthieno[2,3-d]pyrimidin-4-yl)benzonitrile Chemical compound N1=C2SC(C)=CC2=C(C=2C(=CC=CC=2)C#N)N=C1N1CCNCC1 UURUUHYFPCRBID-UHFFFAOYSA-N 0.000 description 1
- UJZWJOQRSMOFMA-UHFFFAOYSA-N 2-chloro-1-(4-fluorophenyl)ethanone Chemical compound FC1=CC=C(C(=O)CCl)C=C1 UJZWJOQRSMOFMA-UHFFFAOYSA-N 0.000 description 1
- VTTHDZKNPJZPEM-UHFFFAOYSA-N 2-chlorothieno[2,3-d]pyrimidine Chemical class ClC1=NC=C2C=CSC2=N1 VTTHDZKNPJZPEM-UHFFFAOYSA-N 0.000 description 1
- ATXVOBUCRXCIQY-UHFFFAOYSA-N 4-(2-bromophenyl)-6-methyl-2-piperazin-1-ylthieno[2,3-d]pyrimidine Chemical compound N1=C2SC(C)=CC2=C(C=2C(=CC=CC=2)Br)N=C1N1CCNCC1 ATXVOBUCRXCIQY-UHFFFAOYSA-N 0.000 description 1
- FVIVKIGLBDRWNR-UHFFFAOYSA-N 4-(2-fluorophenyl)-6-methyl-2-piperazin-1-ylthieno[2,3-d]pyrimidine Chemical compound N1=C2SC(C)=CC2=C(C=2C(=CC=CC=2)F)N=C1N1CCNCC1 FVIVKIGLBDRWNR-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- KBKFNXFQXMSHAW-UHFFFAOYSA-N 5,6-dimethyl-4-phenyl-2-piperazin-1-ylthieno[2,3-d]pyrimidine Chemical compound C=12C(C)=C(C)SC2=NC(N2CCNCC2)=NC=1C1=CC=CC=C1 KBKFNXFQXMSHAW-UHFFFAOYSA-N 0.000 description 1
- PRCNRXJOWBHJHI-UHFFFAOYSA-N 5-methyl-4-phenyl-2-piperazin-1-ylthieno[2,3-d]pyrimidine Chemical compound C=12C(C)=CSC2=NC(N2CCNCC2)=NC=1C1=CC=CC=C1 PRCNRXJOWBHJHI-UHFFFAOYSA-N 0.000 description 1
- AGYHINIFWVREJJ-UHFFFAOYSA-N 6-methyl-4-(2-methylphenyl)-2-piperazin-1-ylthieno[2,3-d]pyrimidine Chemical compound N1=C2SC(C)=CC2=C(C=2C(=CC=CC=2)C)N=C1N1CCNCC1 AGYHINIFWVREJJ-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- 206010036631 Presenile dementia Diseases 0.000 description 1
- 208000035755 Psychosomatic disease Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- BTXFQTKOXJFSRM-UHFFFAOYSA-N acetonitrile;1,1,2-trichloroethene Chemical compound CC#N.ClC=C(Cl)Cl BTXFQTKOXJFSRM-UHFFFAOYSA-N 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 150000001555 benzenes Chemical group 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 208000028683 bipolar I disease Diseases 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- DOBRDRYODQBAMW-UHFFFAOYSA-N copper(i) cyanide Chemical compound [Cu+].N#[C-] DOBRDRYODQBAMW-UHFFFAOYSA-N 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 229960004132 diethyl ether Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 230000003181 encephalopathic effect Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 150000004050 homopiperazines Chemical class 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 239000012433 hydrogen halide Substances 0.000 description 1
- 229910000039 hydrogen halide Inorganic materials 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000006993 memory improvement Effects 0.000 description 1
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002664 nootropic agent Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000004885 piperazines Chemical class 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Chemical group C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Psychiatry (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP59000479A JPS60146891A (ja) | 1984-01-05 | 1984-01-05 | 〔２，３−ｄ〕チエノピリミジン誘導体およびその塩 |
| JP479/84 | 1984-01-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1224782A true CA1224782A (en) | 1987-07-28 |
Family
ID=11474905
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000471183A Expired CA1224782A (en) | 1984-01-05 | 1984-12-28 | Thieno(2,3-d) pyrimidine derivatives and salts thereof |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US4695568A (h) |
| EP (1) | EP0150469B1 (h) |
| JP (1) | JPS60146891A (h) |
| AT (1) | ATE35137T1 (h) |
| CA (1) | CA1224782A (h) |
| DE (1) | DE3472106D1 (h) |
| DK (1) | DK165744C (h) |
| HU (1) | HU191161B (h) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4734418A (en) * | 1984-12-14 | 1988-03-29 | Mitsui Petrochemical Industries, Ltd. | Quinazoline compounds and antihypertensives |
| US4703120A (en) * | 1986-04-28 | 1987-10-27 | Ortho Pharmaceutical Corporation | Furo(3,4-d)pyrimidine-2,4-dione derivatives and intermediates thereof |
| GB8912335D0 (en) * | 1989-05-30 | 1989-07-12 | Smithkline Beckman Intercredit | Compounds |
| DE19636769A1 (de) * | 1996-09-10 | 1998-03-12 | Basf Ag | 3-Substituierte Pyrido [4',3':4,5]thieno[2,3-d]pyrimidin-Derivate, ihre Herstellung und Verwendung |
| JPH10298078A (ja) * | 1997-05-06 | 1998-11-10 | Mitsubishi Chem Corp | 抗不安薬 |
| GB0216027D0 (en) | 2002-07-10 | 2002-08-21 | Arachnova Therapeutics Ltd | New therapeutic use |
| GB0112494D0 (en) * | 2001-05-22 | 2001-07-11 | Arachnova Therapeutics Ltd | New therapeutic use |
| ATE424826T1 (de) * | 2002-07-10 | 2009-03-15 | Dynogen Pharmaceuticals Inc | 4-(2-fluorophenyl)-6-methyl-2(1- piperazinyl)thieno(2,3-d) pyrimidin bei der behandlung von funktionalen darmstörungen |
| DE10232750A1 (de) * | 2002-07-18 | 2004-02-05 | Basf Ag | Verfahren zur Herstellung von macrocyclischen Ketonen durch Dieckmann-Kondensation in der Gasphase |
| CN1678322A (zh) * | 2002-08-29 | 2005-10-05 | 阿瑞科诺沃治疗有限公司 | (4－(2－氟苯基)－6－甲基－2－(1－哌嗪基)噻吩并[2,3－d]嘧啶的新治疗用途 |
| NZ541008A (en) * | 2003-01-13 | 2007-09-28 | Dynogen Pharmaceuticals Inc | Method of treating functional bowel disorders |
| DE602004005814T2 (de) * | 2003-01-13 | 2008-01-10 | Dynogen Pharmaceuticals Inc., Waltham | Verfahren zur behandlung von übelkeit, erbrechen, würgereiz oder jede kombination daraus |
| CA2519379A1 (en) * | 2003-04-04 | 2004-10-21 | Dynogen Pharmaceuticals, Inc. | Method of treating lower urinary tract disorders |
| WO2005002583A1 (en) * | 2003-07-07 | 2005-01-13 | Mitsubishi Pharma Corporation | Use of thieno`2,3-d ! pyrimidines for the prophylaxis or treatment of hyperactivity disorder |
| US20060293309A1 (en) * | 2005-03-28 | 2006-12-28 | Dynogen Pharmaceuticals, Inc. | Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors |
| WO2007120445A1 (en) * | 2006-03-31 | 2007-10-25 | Dynogen Pharmaceuticals, Inc. | SOLUBLE SALTS OF THIENO [2,3-d] PYRIMIDINE DERIVATIVES |
| WO2008051282A2 (en) * | 2006-03-31 | 2008-05-02 | Dynogen Pharmaceuticals, Inc. | Crystalline forms of 4-(2-fluorophenyl)-6-methyl-2-(piperazin-1-yl)thieno(2,3-d)pyrimidine |
| EP2947084B8 (en) * | 2013-01-18 | 2021-03-10 | Guangzhou Maxinovel Pharmaceuticals Co. | Five-and-six-membered heterocyclic compound, and preparation method, pharmaceutical composition and use thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3883651A (en) * | 1969-08-08 | 1975-05-13 | Boehringer Sohn Ingelheim | Pharmaceutical compositions containing a 2-(aminoalkylamino)-4-amino-thieno{8 3,2-d{9 pyrimidine and method of use |
| US4054656A (en) * | 1975-09-10 | 1977-10-18 | Mead Johnson & Company | Thieno[2,3-d]pyrimidine antiallergic agents |
| GB1570494A (en) * | 1975-11-28 | 1980-07-02 | Ici Ltd | Thienopyrimidine derivatives and their use as pesticides |
| ZA782648B (en) * | 1977-05-23 | 1979-06-27 | Ici Australia Ltd | The prevention,control or eradication of infestations of ixodid ticks |
| US4471117A (en) * | 1979-06-21 | 1984-09-11 | Janssen Pharmaceutica N.V. | 3,4-Dihydro-2H-pyrimido(2,1-b)benzothiazoles |
| JPS5692875A (en) * | 1979-12-27 | 1981-07-27 | Dainippon Pharmaceut Co Ltd | 2-aminoquinazoline derivative |
| EP0082023A3 (en) * | 1981-12-16 | 1983-07-20 | Sankyo Company Limited | Thienopyrimidine derivatives, their preparation and their medical use |
| FR2521144A1 (fr) * | 1982-02-08 | 1983-08-12 | Sanofi Sa | Nouveaux derives de la piperazinyl-2 phenyl-4 quinazoline possedant des proprietes antidepressives, methode de preparation desdits composes et medicaments en contenant |
-
1984
- 1984-01-05 JP JP59000479A patent/JPS60146891A/ja active Granted
- 1984-12-20 DK DK617184A patent/DK165744C/da not_active IP Right Cessation
- 1984-12-21 EP EP84116052A patent/EP0150469B1/en not_active Expired
- 1984-12-21 AT AT84116052T patent/ATE35137T1/de not_active IP Right Cessation
- 1984-12-21 DE DE8484116052T patent/DE3472106D1/de not_active Expired
- 1984-12-24 US US06/685,768 patent/US4695568A/en not_active Expired - Lifetime
- 1984-12-28 CA CA000471183A patent/CA1224782A/en not_active Expired
-
1985
- 1985-01-03 HU HU8513A patent/HU191161B/hu unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP0150469B1 (en) | 1988-06-15 |
| EP0150469A1 (en) | 1985-08-07 |
| HU191161B (en) | 1987-01-28 |
| ATE35137T1 (de) | 1988-07-15 |
| DK165744B (da) | 1993-01-11 |
| JPS60146891A (ja) | 1985-08-02 |
| DK617184A (da) | 1985-07-06 |
| US4695568A (en) | 1987-09-22 |
| DK617184D0 (da) | 1984-12-20 |
| DE3472106D1 (en) | 1988-07-21 |
| JPH0367071B2 (h) | 1991-10-21 |
| HUT37435A (en) | 1985-12-28 |
| DK165744C (da) | 1993-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1224782A (en) | Thieno(2,3-d) pyrimidine derivatives and salts thereof | |
| CA1307786C (en) | Quinazoline derivatives and antihypertensive preparations containing same as effective components | |
| US8053579B2 (en) | Salts of clopidogrel and process for preparation | |
| NZ258690A (en) | Pyrrolopyrimidines and pharmaceutical compositions containing such compounds; intermediate pyrrole compounds | |
| AU639043B2 (en) | Pyridazine derivatives, process for their preparation and pharmaceutical compositions containing them | |
| US5852019A (en) | Pyrimidinylpyrazole derivatives | |
| SK147897A3 (en) | Azacycloalcane derivatives, preparation thereof and their applications in therapy | |
| CA1271751A (en) | Dihydroimidazo[1,2-a]pyrimidine derivatives | |
| US4269980A (en) | (Substituted-phenyl)-1,2,4-triazolo[4,3-c]pyrimidines and (substituted-phenyl)-1,2,4-triazolo[1,5-c]pyrimidines | |
| SK3872000A3 (en) | 3-SUBSTITUTED TETRAHYDROPYRIDOPYRIMIDINONE DERIVATIVES, METHODì (54) FOR PRODUCING THE SAME, AND THEIR USE | |
| KR19980702114A (ko) | 치료에 유용한 비시클릭 이소티오우레아 유도체 | |
| Cho et al. | Ring closure reactions of methyl N‐(haloacetyl) anthranilates with ammonia | |
| US4556739A (en) | 3,4-Dialkoxy-2-alkylcarbonyl analino compounds | |
| US3993650A (en) | Pyrrolo [3,4-d] pyrimidines | |
| JPH0321553B2 (h) | ||
| JPH0616557A (ja) | 脳機能障害改善剤 | |
| Morel et al. | 2-aza-1, 3-dienes with electron-releasing substituents at the 1, 3 positions. Reagents for the construction of pyridine and pyrimidine derivatives | |
| KR900005018B1 (ko) | 1-아로일-5-옥소-2-피롤리딘프로판산과 그의 에스테르 및 제조방법 | |
| JP2875605B2 (ja) | ３―エキソメチレンピロロ［２，１―ｂ］チアゾール誘導体 | |
| CA1049017A (en) | Pyrrolo (3,4-b) pyridines and methods for their preparation | |
| CA1045135A (en) | Pyrrolo(3,4-d)pyrimidines and methods for their preparation | |
| JPH0548208B2 (h) | ||
| Muller et al. | Regioselective Synthesis of 2‐oxo‐2, 8‐dihydro‐[l, 2, 4] oxadiazolo [2, 3‐a] pyrimidine‐7‐carbamates: A New Class of Antihypertensive Peripheral Vasodilators | |
| CA1150252A (en) | Guanidines, processes for producing them, and pharmaceutical preparations containing such compounds | |
| NO146281B (no) | Analogifremgangsmaate for fremstilling av terapeutisk virksomme 3-amino-4-karbamyl-pyrrolderivater |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEX | Expiry |